Literature DB >> 32588968

Access site related vascular complications with third generation transcatheter heart valve systems.

Hendrik Ruge1,2, Melchior Burri1,2, Magdalena Erlebach1,2, Ruediger Lange1,2.   

Abstract

OBJECTIVES: This study examines the impact of anatomical and procedural factors on Valve Academic Research Consortium-2-defined vascular complications at the femoral access site in transcatheter aortic valve replacement (TAVR) with third generation transcatheter heart valve (THV)-systems.
BACKGROUND: Randomized clinical trials reported on vascular complications with current THV-systems. However, clinical presentation and consequences of these events are not well studied.
METHODS: All patients who underwent a transfemoral TAVR using an Edwards Sapien3®/Sapien3ultra® or a Medtronic Evolut-R®/Evolut-PRO® have been identified from our institutional database. Only procedures utilizing the PerClose-ProGlide® vascular closure device were included. Risk factors for vascular complications were analyzed with a logistic regression model. Preoperative and procedural data were collected. The postoperative course of patients with and without vascular complications was compared.
RESULTS: A total of 878 patients met the inclusion criteria. Of these, 152 patients (17.3%) had an access-site related vascular complication (87 major complications, 9.9%). Sheath-to-femoral-artery-ratio (SFAR) (OR per 0.1 increase = 1.35, p < .001) and more than 2 vessel entries with large bore sheaths (OR = 1.76, p = .029) were independent risk factors for vascular complications. Female gender (OR = 1.44, p = .07) and two vessel entries with large bore sheaths (OR = 1.2, p = .53) increased the risk, although no statistical significance was shown. Age (OR = 1.07, p = .62), body mass index (OR = 1.1 per 5 points, p = .32) and vessel wall calcification at puncture site (OR = 0.93, p = .7) had no influence on vascular complications. Patients with vascular complications had a higher need for blood transfusion (p < .001) and a higher in-hospital mortality (2.6 vs. 0.4%, p = .019).
CONCLUSIONS: Procedural risk assessment should include SFAR calculation and consider the need for large bore sheath exchange. This might reduce the vascular trauma, lower vascular complication rates and improve the clinical outcome after TAVR.
© 2020 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.

Entities:  

Keywords:  percutaneous valve therapy; transcatheter valve implantation; vascular closure device

Year:  2020        PMID: 32588968     DOI: 10.1002/ccd.29095

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

Review 1.  Strategies for Facilitating Totally Percutaneous Transfemoral TAVR Procedures.

Authors:  Amnon Eitan; Hussein Sliman; Avinoam Shiran; Ronen Jaffe
Journal:  J Clin Med       Date:  2022-04-09       Impact factor: 4.964

2.  Pledget-assisted hemostasis to fix residual access-site bleedings after double pre-closure technique.

Authors:  Francesco Burzotta; Cristina Aurigemma; Mila Kovacevic; Enrico Romagnoli; Stefano Cangemi; Francecso Bianchini; Marialisa Nesta; Piergiorgio Bruno; Carlo Trani
Journal:  World J Cardiol       Date:  2022-05-26

3.  Transcatheter aortic valve replacement using the iSleeve expandable sheath in small femoral arteries.

Authors:  Natalie Glaser; Crochan J O'Sullivan; Nawzad Saleh; Dinos Verouhis; Magnus Settergren; Rickard Linder; Andreas Rück
Journal:  Open Heart       Date:  2021-10

4.  A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation.

Authors:  Gregor Heitzinger; Christina Brunner; Sophia Koschatko; Varius Dannenberg; Katharina Mascherbauer; Kseniya Halavina; Carolina Doná; Matthias Koschutnik; Georg Spinka; Christian Nitsche; Markus Mach; Martin Andreas; Florian Wolf; Christian Loewe; Christoph Neumayer; Michael Gschwandtner; Andrea Willfort-Ehringer; Max-Paul Winter; Irene M Lang; Philipp E Bartko; Christian Hengstenberg; Georg Goliasch
Journal:  Front Cardiovasc Med       Date:  2022-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.